Impact of Chiral Bioanalytical Methods on the Bioequivalence of Ibuprofen Products Containing Ibuprofen Lysinate and Ibuprofen Base
Por:
Garcia-Arieta, A, Ferrero-Cafiero, JM, Puntes, M, Gich, I, Morales-Alcelay, S, Tarre, M, Font, X, Antonijoan, RM
Publicada:
1 may 2016
Resumen:
The purpose was to assess the impact of the use of a chiral bioanalytical method on the conclusions of a bioequivalence study that compared two ibuprofen suspensions with different rates of absorption. A comparison of the conclusion of bioequivalence between a chiral method and an achiral approach was made. Plasma concentrations of R-ibuprofen and S-ibuprofen were determined using a chiral bioanalytical method; bioequivalence was tested for R-ibuprofen and for S-ibuprofen separately and for the sum of both enantiomers as an approach for an achiral bioanalytical method. The 90% confidence interval (90% CI) that would have been obtained with an achiral bioanalytical method (90% CI: C-max: 117.69-134.46; AUC(0)(t): 104.75-114.45) would have precluded the conclusion of bioequivalence. This conclusion cannot be generalized to the active enantiomer (90% CI: C-max: 103.36-118.38; AUC(0)(t): 96.52-103.12), for which bioequivalence can be concluded, and/or the distomer (90% CI: C-max: 132.97-151.33; AUC(0)(t): 115.91-135.77) for which a larger difference was observed. Chiral bioanalytical methods should be required when 1) the enantiomers exhibit different pharmacodynamics and 2) the exposure (AUC or C-max) ratio of enantiomers is modified by a difference in the rate of absorption. Furthermore, the bioequivalence conclusion should be based on all enantiomers, since the distomer(s) might not be completely inert, in contrast to what is required in the current regulatory guidelines. In those cases where it is unknown if the ratio between enantiomers is modified by changing the rate of absorption, chiral bioanalytical methods should be employed unless enantiomers exhibit the same pharmacodynamics. (C) 2016 Wiley Periodicals, Inc.
Filiaciones:
Garcia-Arieta, A:
Spanish Agcy Med & Hlth Care Prod, Div Pharmacol & Clin Evaluat, Dept Human Use Med, Madrid, Spain
Ferrero-Cafiero, JM:
Hosp Santa Creu & St Pau CIM St Pau, Inst Recerca, Ctr Invest Medicaments, Barcelona, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, Hosp Santa Creu & St Pau, Farmacol Clin, E-08193 Barcelona, Spain
Puntes, M:
Hosp Santa Creu & St Pau CIM St Pau, Inst Recerca, Ctr Invest Medicaments, Barcelona, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, Hosp Santa Creu & St Pau, Farmacol Clin, E-08193 Barcelona, Spain
Gich, I:
Hosp Santa Creu & St Pau CIM St Pau, Inst Recerca, Ctr Invest Medicaments, Barcelona, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, Hosp Santa Creu & St Pau, Farmacol Clin, E-08193 Barcelona, Spain
Morales-Alcelay, S:
Spanish Agcy Med & Hlth Care Prod, Div Pharmacol & Clin Evaluat, Dept Human Use Med, Madrid, Spain
Tarre, M:
Lab Aplicac Farmacodinam SA FARDI, Barcelona, Spain
Font, X:
Lab Aplicac Farmacodinam SA FARDI, Barcelona, Spain
Antonijoan, RM:
Hosp Santa Creu & St Pau CIM St Pau, Inst Recerca, Ctr Invest Medicaments, Barcelona, Spain
Univ Autonoma Barcelona, Dept Farmacol & Terapeut, Hosp Santa Creu & St Pau, Farmacol Clin, E-08193 Barcelona, Spain
|